BRAF and cancer: However, they do show more adverse morphological features which corresponds with their aggressive phenotype such as frequent tumour budding, a lack of tumour-infiltrating lymphocytes, frequent lymphatic, perineural, and venous invasion and increased lymph node metastases compared to BRAF mutant/MSI and BRAF wild-type cancers [81–83].